2 waves of start dates. November and January depending on territory.
2 week training.
Call on GI and primary care
2 week training.
Call on GI and primary care
-
Thurs news: Lilly’s weight-loss drug prevents diabetes. Merck pays $588M for bispecific. Amgen speaks out about bone density issues with obesity drug. PTC gets gene therapy approval. JNJ’s 340B legal fight. See more on our front page
Phathom
- Thread starter anonymous
- Start date
-
- Tags
- None
Training remote? In person? Hybrid? If in person what is location
Heard that training is virtual.
National launch meeting early next year.
November & January hiring waves.
Base: $100k - $140k.
$40k bonus.
Fleet vehicle.
Great PPO health insurance.
401k with matching.
Paid time off
Shut down between Christmas & New Years.
Voquenza Dual & Triple pack 14 day regimens already FDA approved for H-pylori. On GoodRx they're $800-$900.
On track with studies to obtain erosive & non-erosive gerd indications.
FDA requested more product stabilization information, which delayed launch & hiring.
Vonoprazan is first PCAB to launch in U.S. Phathom has licensing rights from Takeda in Canada & Europe too.
The ee healing rates are 95% vs ppis near 80%.
Rapid onset day 1 vs 3-5 days with ppis
Potent by binding with stimulated and resting parietal cells. Does not require acid to be activated. Achieves target 24-hour acid suppression within 2 hours of a single dose.
Durable with 7 hour half life vs <2 hours with ppis.10 to 100 fold better acid control vs Prevacid and Nexium.
Managed care coverage is what makes or breaks the first novel treatment of gerd in 30 years.
Great corporate culture with CEO coming from Celgene.
National launch meeting early next year.
November & January hiring waves.
Base: $100k - $140k.
$40k bonus.
Fleet vehicle.
Great PPO health insurance.
401k with matching.
Paid time off
Shut down between Christmas & New Years.
Voquenza Dual & Triple pack 14 day regimens already FDA approved for H-pylori. On GoodRx they're $800-$900.
On track with studies to obtain erosive & non-erosive gerd indications.
FDA requested more product stabilization information, which delayed launch & hiring.
Vonoprazan is first PCAB to launch in U.S. Phathom has licensing rights from Takeda in Canada & Europe too.
The ee healing rates are 95% vs ppis near 80%.
Rapid onset day 1 vs 3-5 days with ppis
Potent by binding with stimulated and resting parietal cells. Does not require acid to be activated. Achieves target 24-hour acid suppression within 2 hours of a single dose.
Durable with 7 hour half life vs <2 hours with ppis.10 to 100 fold better acid control vs Prevacid and Nexium.
Managed care coverage is what makes or breaks the first novel treatment of gerd in 30 years.
Great corporate culture with CEO coming from Celgene.
Phathom Pharmaceuticals Receives Buy Rating and Shows Positive Momentum in Biopharmaceutical Industry - Best Stocks
Phathom Pharmaceuticals Receives Buy Rating and Shows Positive Momentum in Biopharmaceutical Industry
Phathom Pharmaceuticals Receives Buy Rating and Shows Positive Momentum in Biopharmaceutical Industry
Phathom Pharmaceuticals Receives Buy Rating and Shows Positive Momentum in Biopharmaceutical Industry
by Roberto Liccardo
September 11, 2023
Phathom Pharmaceuticals, Inc. (NASDAQ
HAT) has received a “Buy” rating from seven different ratings firms, according to Bloomberg Ratings. This positive sentiment from analysts is reflected in the average one-year price target of $23.33 for the stock.
On Friday, shares of Phathom Pharmaceuticals opened at $12.74. Over the past year, the stock has experienced a low of $5.84 and a high of $17.02. With a current ratio and quick ratio both at 11.96, the company shows strong financial stability. However, it does have a debt-to-equity ratio of 5.56.
With a market capitalization of $723.67 million and a PE ratio of -2.91, Phathom Pharmaceuticals is positioned as a smaller player in the biopharmaceutical industry. Its beta of 0.45 indicates that it is less volatile than the market as a whole.
The stock has been showing positive momentum with its 50-day moving average at $14.38 and its two-hundred day moving average at $11.75.
As a biopharmaceutical company, Phathom Pharmaceuticals focuses on developing and commercializing treatments for gastrointestinal diseases. Its main product is an investigational potassium-competitive acid blocker (P-CAB), which effectively blocks acid secretion in the stomach.
In its most recent quarterly earnings report released on August 10th, Phathom Pharmaceuticals reported earnings per share (EPS) of ($0.84). This beat the consensus estimate of ($0.95) by $0.11, indicating better-than-expected performance.
Looking ahead, research analysts anticipate that Phathom Pharmaceuticals will post an EPS of -4.07 for the current fiscal year.
With positive ratings from investment analysts and promising developments in its product portfolio, Phathom Pharmaceuticals appears to be on track for growth and success in the coming year.
September 11, 2023
Phathom Pharmaceuticals, Inc. (NASDAQ
HAT) has received a “Buy” rating from seven different ratings firms, according to Bloomberg Ratings. This positive sentiment from analysts is reflected in the average one-year price target of $23.33 for the stock.On Friday, shares of Phathom Pharmaceuticals opened at $12.74. Over the past year, the stock has experienced a low of $5.84 and a high of $17.02. With a current ratio and quick ratio both at 11.96, the company shows strong financial stability. However, it does have a debt-to-equity ratio of 5.56.
With a market capitalization of $723.67 million and a PE ratio of -2.91, Phathom Pharmaceuticals is positioned as a smaller player in the biopharmaceutical industry. Its beta of 0.45 indicates that it is less volatile than the market as a whole.
The stock has been showing positive momentum with its 50-day moving average at $14.38 and its two-hundred day moving average at $11.75.
As a biopharmaceutical company, Phathom Pharmaceuticals focuses on developing and commercializing treatments for gastrointestinal diseases. Its main product is an investigational potassium-competitive acid blocker (P-CAB), which effectively blocks acid secretion in the stomach.
In its most recent quarterly earnings report released on August 10th, Phathom Pharmaceuticals reported earnings per share (EPS) of ($0.84). This beat the consensus estimate of ($0.95) by $0.11, indicating better-than-expected performance.
Looking ahead, research analysts anticipate that Phathom Pharmaceuticals will post an EPS of -4.07 for the current fiscal year.
With positive ratings from investment analysts and promising developments in its product portfolio, Phathom Pharmaceuticals appears to be on track for growth and success in the coming year.
All the above info stands to be true but launch for EVERYONE is November!
It is my understanding that some territories will not start until middle of January. Has that changed? Anyone get offer letters yet? How long did background check/ drug test take etc?
Yes it changed this week to fill sales force hire in November.
Background checks took about 10 days to two weeks to complete if I recall, but no word yet from HR on drug testing timeline/dates…assuming we’ll get notified any day now.
Has anyone applied for a religious exemption for the vaccination requirement? If so, how did it turn out?
Had to submit to a cavity search, but in the end, I got more.
This is what the recruiter told me regarding start date.
Same. Was told territory interviewing for won’t start til Jan. Really hoping that is still the case. Did not hear that it had changed. Has anyone else heard that? (Still need to get the offer -won’t be a problem if I don’t get the job ha)
Hasn’t changed. I’d imagine they’ll have the January spots filled by late October/early November…